R&D News | pharmaphorum

News

Black and white image of the side of a baby's face, focused on its ear

Lilly allies with gene-editing firm Seamless on hearing loss

Gene-editing firm Seamless Therapeutics has attracted its first major pharma partner, Eli Lilly, with a $1.12bn alliance focused on hearing loss.

News

Boehringer drug scores in rare kidney disease FSGS

Boehringer's TRPC6 inhibitor apecotrep, formerly developed for COVID-19, has shown efficacy in the rare kidney disease FSGS in a phase 2 trial.

News

UK biotech sees "strong finish" to 2025 financing

2025 was a challenging year for the UK biotech sector, but it ended the year with signs of "renewed confidence," says the BIA industry body.

News

Boehringer signs €1bn+ deal for Simcere IBD candidate

Boehringer Ingelheim has sourced an IL-23p19xTL1A bispecific antibody for inflammatory bowel disease, from China's Simcere, for €42m upfront.

News

Roche claims midstage win for obesity injectable

Roche reports weight loss of up to 22.5% with its injectable GIP/GLP-1 agonist obesity drug, setting up phase 3, but will it be too late to the table?

News

Introducing the Sunday Times Tech 100: Life sciences part 2

In our second of three reports on the 2026 Sunday Times Tech 100, we focus on the first nine of 18 life sciences companies in the hardware category.

Lilly allies with gene-editing firm Seamless on hearing loss

Boehringer drug scores in rare kidney disease FSGS

UK biotech sees "strong finish" to 2025 financing

Boehringer signs €1bn+ deal for Simcere IBD candidate

Roche claims midstage win for obesity injectable

Introducing the Sunday Times Tech 100: Life sciences part 2

ESMO26: Sac-TMT delivers the goods in PD-L1-negative NSCLC

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks